Sigma-Aldrich Announced Launch of New Identity for its Fine Chemicals Business


Sigma-Aldrich Corporation announced a new identity for its fine chemicals business that ties together all the progress it has made over the past five years. The new brand, called SAFC, will also embrace recent acquisitions, Ultrafine and Tetrionics. The SAFC brand will have annual sales exceeding $250 million, with over 650 of Sigma-Aldrich's 6,000 employees dedicated to its success.

SAFC's global headquarters will be based in St. Louis and its European HQ in Munich. Its largest manufacturing sites are located in facilities in the UK in Manchester, Gillingham and Irvine, Scotland; in Buchs, Switzerland; and in the USA in St. Louis, MO, and Sheboygan and Madison, WI. All of these facilities contain cGMP manufacturing capabilities. SAFC will comprise three customer solutions-focused business segments, SAFC Pharma, SAFC Specialties and SAFC Hitech:

SAFC Pharma

Focused on cGMP manufacturing, process development and contract services for both small organic APIs and advanced intermediates and the development of large molecule biopharmaceuticals, SAFC Pharma provides custom support from preclinical stage through clinical development to commercialization. Many years of experience, world-class project management, dedicated technology teams, FDA-approved facilities, combined with extensive process development and scale up knowledge, and full regulatory compliance ensure that customers' products get to market faster, adding true value to their pharmaceutical development process.

SAFC Specialties

Dedicated to its broadest customer base, SAFC Specialties provides a diverse range of raw materials. Regulatory expertise, extensive QC facilities, and a dedication to flexible, quality service make SAFC Specialties the preferred partner of choice for cost effective materials. Its specific market sectors include:

- Flavours and Fragrances

- Diagnostic OEM and Raw Materials

- Raw Materials for Pharmaceuticals, Biopharmaceuticals and other High Technology Industries

SAFC Hitech

Targeted at the performance materials market, SAFC Hitech supports its customers' needs from development through commercialization. Its core strength lies in our ability to take an idea and bring a product to market quickly while maximizing value for its customers. SAFC Hitech leverages its chemical technology to optimize a specific application's performance, resulting in fast, innovative chemical solutions that provide its customers with a competitive edge.

Commenting on the launch, SAFC's President, Frank Wicks, stated: "As part of Sigma-Aldrich, we want to take advantage of all of the strengths our parent and its great brand name have earned. But, the message we want to convey is that we are distinct and different from the catalogue end of the business; that SAFC is a producer in its own right. We also want people to know that SAFC is not the company we were five years ago. Our new identity reflects our commitment to become the global leader in custom services and builds upon the momentum of our recent acquisitions. SAFC will draw upon the experience of the former fine chemicals business and be backed by the full financial strength of our parent, Sigma-Aldrich, as we seek to build further upon our position as a major player in custom synthesis."

Wicks continued: "Our capabilities to provide products and services throughout the drug development pipeline, our presence in all major global pharmaceutical markets, our world-class project management team and access to over 250 PhD scientists give SAFC a unique platform for growth within the pharmaceutical sector. We expect to continue to invest extensively in new capacity, technology and personnel."

SAFC anticipates that much of its expected growth will come from the pharmaceutical sector. Acquisitions and extensive investment in cGMP facilities at many of its global manufacturing sites have enhanced its capabilities to offer a wide range of bio and organic pharmaceutical services from pre-clinical through large-scale manufacture. Longer term, additional opportunities for growth are expected in the Hitech segment as we continue to add to our capabilities to meet customer expectations in this faster growth market.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics